/Companies

Revagenix

2 known investors

Find your way into Revagenix

Sign up to see every warm intro you have to Revagenix

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Revagenix team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs. Its lead program, Rev-56, is an inhaled therapy with a novel mechanism of action designed for non-CF bronchiectasis (NCFB).

Founders & leadership

RCRyan Cirz
Ryan CirzCo-founder & CEO
AMAndrew McCandlish
Andrew McCandlishCo-founder & COOAndrew McCandlish is co-founder and COO of Revagenix, a precision-therapeutics company developing drugs for serious chronic diseases. He has prior experience in corporate development, R&D strategy, and program leadership across biotechnology, pharmaceuticals, and medical devices, and has published scientific work.
PSPeter Smith
Peter SmithChief Scientific Officer
DCDaniel Cloutier
Daniel CloutierVP, Development

Investors · 2

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Frequently asked questions

What does Revagenix do?
Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs. Its lead program, Rev-56, is an inhaled therapy with a novel mechanism of action designed for non-CF bronchiectasis (NCFB).
Who founded Revagenix?
Revagenix was founded by Ryan Cirz, Andrew McCandlish.
Who are Revagenix's investors?
Revagenix's investors include Tenmile, Novo Holdings.